journal

European Heart Journal

journal
https://read.qxmd.com/read/32232396/recommendations-from-the-peking-union-medical-college-hospital-for-the-management-of-acute-myocardial-infarction-during-the-covid-19-outbreak
#1
Zhi-Cheng Jing, Hua-Dong Zhu, Xiao-Wei Yan, Wen-Zhao Chai, Shuyang Zhang
No abstract text is available yet for this article.
March 31, 2020: European Heart Journal
https://read.qxmd.com/read/32232395/initial-covid-19-affecting-cardiac-patients-in-china
#2
Yaling Han
No abstract text is available yet for this article.
March 31, 2020: European Heart Journal
https://read.qxmd.com/read/32227240/reduction-of-cardiovascular-risk-in-patients-with-t2dm-by-glp-1-receptor-agonists-a-shift-in-paradigm-driven-by-data-from-large-cardiovascular-outcome-trials
#3
https://read.qxmd.com/read/32227235/the-haemochromatosis-gene-hfe-and-kupffer-cells-control-ldl-cholesterol-homeostasis-and-impact-on-atherosclerosis-development
#4
Egon Demetz, Piotr Tymoszuk, Richard Hilbe, Chiara Volani, David Haschka, Christiane Heim, Kristina Auer, Daniela Lener, Lucas B Zeiger, Christa Pfeifhofer-Obermair, Anna Boehm, Gerald J Obermair, Cornelia Ablinger, Stefan Coassin, Claudia Lamina, Juliane Kager, Verena Petzer, Malte Asshoff, Andrea Schroll, Manfred Nairz, Stefanie Dichtl, Markus Seifert, Laura von Raffay, Christine Fischer, Marina Barros-Pinkelnig, Natascha Brigo, Lara Valente de Souza, Sieghart Sopper, Jakob Hirsch, Michael Graber, Can Gollmann-Tepeköylü, Johannes Holfeld, Julia Halper, Sophie Macheiner, Johanna Gostner, Georg F Vogel, Raimund Pechlaner, Patrizia Moser, Medea Imboden, Pedro Marques-Vidal, Nicole M Probst-Hensch, Heike Meiselbach, Konstantin Strauch, Annette Peters, Bernhard Paulweber, Johann Willeit, Stefan Kiechl, Florian Kronenberg, Igor Theurl, Ivan Tancevski, Guenter Weiss
AIMS: Imbalances of iron metabolism have been linked to the development of atherosclerosis. However, subjects with hereditary haemochromatosis have a lower prevalence of cardiovascular disease. The aim of our study was to understand the underlying mechanisms by combining data from genome-wide association study analyses in humans, CRISPR/Cas9 genome editing, and loss-of-function studies in mice. METHODS AND RESULTS: Our analysis of the Global Lipids Genetics Consortium (GLGC) dataset revealed that single nucleotide polymorphisms (SNPs) in the haemochromatosis gene HFE associate with reduced low-density lipoprotein cholesterol (LDL-C) in human plasma...
March 30, 2020: European Heart Journal
https://read.qxmd.com/read/32227233/time-to-rename-the-middle-child-of-heart-failure-heart-failure-with-mildly-reduced-ejection-fraction
#5
Carolyn S P Lam, Adriaan A Voors, Ponikowski Piotr, John J V McMurray, Scott D Solomon
No abstract text is available yet for this article.
March 30, 2020: European Heart Journal
https://read.qxmd.com/read/32227182/periprocedural-myocardial-injury-in-the-excel-trial
#6
Johannes L Bjørnstad, Bjørn Bendz
No abstract text is available yet for this article.
March 30, 2020: European Heart Journal
https://read.qxmd.com/read/32227172/2019-vs-2016-esc-eas-statin-guidelines-for-primary-prevention-of-atherosclerotic-cardiovascular-disease
#7
Martin Bødtker Mortensen, Børge Grønne Nordestgaard
AIMS : The 2019 vs. 2016 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) dyslipidaemia guidelines contains new recommendations for primary prevention with statins; however, the potential impact of these changes is unclear. We compared the 2019 and 2016 guidelines regarding statin eligibility and potential impact on prevention of atherosclerotic cardiovascular disease (ASCVD) in the general population. METHODS AND RESULTS : We examined 45 750 individuals aged 40-75 from the Copenhagen General Population Study, all free of ASCVD and statin use at baseline...
March 30, 2020: European Heart Journal
https://read.qxmd.com/read/32227168/considerations-for-an-optimal-definition-of-procedural-myocardial-infarction
#8
Gregg W Stone, Ori Ben-Yehuda, Joseph F Sabik, A Pieter Kappetein, Patrick W Serruys
No abstract text is available yet for this article.
March 30, 2020: European Heart Journal
https://read.qxmd.com/read/32227166/febuxostat-and-atrial-fibrillation
#9
Masanari Kuwabara, Claudio Borghi, Richard J Johnson
No abstract text is available yet for this article.
March 30, 2020: European Heart Journal
https://read.qxmd.com/read/32227120/acute-pulmonary-embolism-and-covid-19-pneumonia-a-random-association
#10
Gian Battista Danzi, Marco Loffi, Gianluca Galeazzi, Elisa Gherbesi
No abstract text is available yet for this article.
March 30, 2020: European Heart Journal
https://read.qxmd.com/read/32227076/life-threatening-cardiac-tamponade-complicating-myo-pericarditis-in-covid-19
#11
Alina Hua, Kevin O'Gallagher, Daniel Sado, Jonathan Byrne
No abstract text is available yet for this article.
March 30, 2020: European Heart Journal
https://read.qxmd.com/read/32221596/a-putative-placebo-analysis-of-the-effects-of-sacubitril-valsartan-in-heart-failure-across-the-full-range-of-ejection-fraction
#12
Muthiah Vaduganathan, Pardeep S Jhund, Brian L Claggett, Milton Packer, Jiri Widimský, Petar Seferovic, Adel Rizkala, Martin Lefkowitz, Victor Shi, John J V McMurray, Scott D Solomon
AIMS: The PARADIGM-HF and PARAGON-HF trials tested sacubitril/valsartan against active controls given renin-angiotensin system inhibitors (RASi) are ethically mandated in heart failure (HF) with reduced ejection fraction and are used in the vast majority of patients with HF with preserved ejection fraction. To estimate the effects of sacubitril/valsartan had it been tested against a placebo control, we made indirect comparisons of the effects of sacubitril/valsartan with putative placebos in HF across the full range of left ventricular ejection fraction (LVEF)...
March 28, 2020: European Heart Journal
https://read.qxmd.com/read/32221588/hypertensive-coronary-microvascular-dysfunction-a-subclinical-marker-of-end-organ-damage-and-heart-failure
#13
Wunan Zhou, Jenifer M Brown, Navkaranbir S Bajaj, Alvin Chandra, Sanjay Divakaran, Brittany Weber, Courtney F Bibbo, Jon Hainer, Viviany R Taqueti, Sharmila Dorbala, Ron Blankstein, Dale Adler, Patrick O'Gara, Marcelo F Di Carli
AIMS: Hypertension is a well-established heart failure (HF) risk factor, especially in the context of adverse left ventricular (LV) remodelling. We aimed to use myocardial flow reserve (MFR) and global longitudinal strain (GLS), markers of subclinical microvascular and myocardial dysfunction, to refine hypertensive HF risk assessment. METHODS AND RESULTS: Consecutive patients undergoing symptom-prompted stress cardiac positron emission tomography (PET)-computed tomography and transthoracic echocardiogram within 90 days without reduced left ventricular ejection fraction (<40%) or flow-limiting coronary artery disease (summed stress score ≥ 3) were included...
March 28, 2020: European Heart Journal
https://read.qxmd.com/read/32221587/comparison-of-interleukin-6-c-reactive-protein-and-low-density-lipoprotein-cholesterol-as-biomarkers-of-residual-risk-in-contemporary-practice-secondary-analyses-from-the-cardiovascular-inflammation-reduction-trial
#14
Paul M Ridker, Jean G MacFadyen, Robert J Glynn, Gary Bradwin, Ahmed A Hasan, Nader Rifai
AIMS: In epidemiologic cohorts initiated >30 years ago, inflammatory biomarkers, such as interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP) were shown to independently predict future cardiovascular events with a magnitude of effect comparable to that of low-density lipoprotein cholesterol (LDLC). Whether aggressive contemporary therapy for atherosclerosis has altered these relationships is unknown yet has major implications for future drug development. METHODS AND RESULTS: Interleukin-6, hsCRP, and LDLC were measured at baseline in up to 4168 North American patients enrolled in the contemporary Cardiovascular Inflammation Reduction Trial with prior myocardial infarction or multivessel coronary disease who additionally had diabetes or metabolic syndrome and were followed for a period of up to 5 years for incident major recurrent cardiovascular events and all-cause mortality...
March 28, 2020: European Heart Journal
https://read.qxmd.com/read/32221582/effects-of-dapagliflozin-in-dapa-hf-according-to-background-heart-failure-therapy
#15
Kieran F Docherty, Pardeep S Jhund, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, David L DeMets, Marc S Sabatine, Olof Bengtsson, Mikaela Sjöstrand, Anna Maria Langkilde, Akshay S Desai, Mirta Diez, Jonathan G Howlett, Tzvetana Katova, Charlotta E A Ljungman, Eileen O'Meara, Mark C Petrie, Morten Schou, Subodh Verma, Pham Nguyen Vinh, Scott D Solomon, John J V McMurray
AIMS: In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined whether this benefit was consistent in relation to background HF therapy. METHODS AND RESULTS: In this post hoc analysis, we examined the effect of study treatment in the following yes/no subgroups: diuretic, digoxin, mineralocorticoid receptor antagonist (MRA), sacubitril/valsartan, ivabradine, implanted cardioverter-defibrillating (ICD) device, and cardiac resynchronization therapy...
March 28, 2020: European Heart Journal
https://read.qxmd.com/read/32211888/proceedings-from-the-3rd-european-clinical-consensus-conference-for-clinical-trials-in-device-based-hypertension-therapies
#16
Felix Mahfoud, Michel Azizi, Sebastian Ewen, Atul Pathak, Christian Ukena, Peter J Blankestijn, Michael Böhm, Michel Burnier, Gilles Chatellier, Isabelle Durand Zaleski, Guido Grassi, Michael Joner, David E Kandzari, Ajay Kirtane, Sverre E Kjeldsen, Melvin D Lobo, Thomas F Lüscher, John William McEvoy, Gianfranco Parati, Patrick Rossignol, Luis Ruilope, Markus P Schlaich, Atif Shahzad, Faisal Sharif, Andrew S P Sharp, Horst Sievert, Massimo Volpe, Michael A Weber, Roland E Schmieder, Costas Tsioufis, William Wijns
No abstract text is available yet for this article.
March 25, 2020: European Heart Journal
https://read.qxmd.com/read/32211887/acrolein-exposure-from-electronic-cigarettes
#17
Bernd Mayer
No abstract text is available yet for this article.
March 25, 2020: European Heart Journal
https://read.qxmd.com/read/32211878/acrolein-e-cigarettes-and-pulmonary-and-vascular-damage
#18
Marin Kuntic, Andreas Daiber, Thomas Münzel
No abstract text is available yet for this article.
March 25, 2020: European Heart Journal
https://read.qxmd.com/read/32211876/the-role-of-implantable-cardioverter-defibrillators-in-asymptomatic-patients-with-left-ventricular-dysfunction
#19
Ilan Goldenberg, David T Huang, Jens Cosedis Nielsen
No abstract text is available yet for this article.
March 25, 2020: European Heart Journal
https://read.qxmd.com/read/32211875/the-role-of-implantable-cardioverter-defibrillators-in-new-york-heart-class-i-heart-failure-patients-do-not-abandon-the-asymptomatic-just-yet
#20
Anne-Lotte C J van der Lingen, Cornelis P Allaart
No abstract text is available yet for this article.
March 25, 2020: European Heart Journal
journal
journal
20101
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"